Impact of posaconazole and diltiazem on pharmacokinetics of encorafenib, a BRAF V600 kinase inhibitor for melanoma and colorectal cancer with BRAF mutations

• Autori principali: Erik Hahn (Autore), Renae Chavira (Autore), Lance Wollenberg (Autore), Weiwei Tan (Autore), Micaela B. Reddy (Autore)
• Natura: Libro
• Pubblicazione: Wiley, 2023-12-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Abstract Encorafenib is a potent and selective ATP competitive inhibitor of BRAF V600-mutant kinase approved for patients with BRAF‐mutant melanoma and colorectal cancer. Encorafenib is mainly metabolized by cytochrome P450 (CYP) 3A4 in vitro and may be susceptible to drug-drug interactions when co‐...